Chandan Healthcare Limited held a virtual analysts' and investors' meeting on June 30, 2026, to engage with key market stakeholders. The session was conducted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The interaction followed a question-and-answer format, and no presentation was made by the company officials during the event. No Unpublished Price Sensitive Information (UPSI) was shared or discussed during the meeting.

The meeting saw participation from 32 attendees, including representatives from various financial institutions and High Net-Worth Individuals (HNIs). The participants engaged with the company management through a webinar format during the scheduled time slot from 02:35 PM to 03:30 PM IST.

Attendee Details

The following table details the organizations and investor names that participated in the meeting:

Chandan Healthcare Limited reported a 21.4% increase in reported net profit to ₹27.06 Cr for the financial year ended March 31, 2026, while total income rose 20.4% to ₹280.67 Cr. The company achieved this growth through a balanced business model spanning B2C retail diagnostics, B2B institutional partnerships, and B2G government PPP contracts across 62 cities and 16 states. EBITDA for the year surged 31% to ₹56.84 Cr, with margins expanding to 20.25% from 18.62% in the previous year.

For the quarter ended March 31, 2026 (Q4 FY26), the company posted a reported net profit of ₹6.92 Cr, an increase of 14.9% from ₹6.02 Cr in the corresponding period of the previous year. Total income for Q4 FY26 stood at ₹77.41 Cr, compared to ₹65.07 Cr in Q4 FY25. EBITDA for the quarter was ₹14.25 Cr, with margins at 18.41%. The operational performance was supported by an aggressive multi-city rollout of exclusive partnerships and government PPP projects with a 10-year tenure ensuring long-term revenue visibility across Punjab, Assam, and Haryana.

Consolidated Financial Performance

The company’s financial statements for FY26 reflect strong growth across key metrics. Operating income for the year reached ₹276.39 Cr, up from ₹230.12 Cr in FY25. Total expenditure increased to ₹223.83 Cr from ₹189.67 Cr in the prior year. Profit before tax (PBT) for FY26 was ₹41.18 Cr, a rise of 28.4% from ₹32.07 Cr in FY25. Minority interest for the year was reported at ₹1.50 Cr.

Q4 & FY26 Profit & Loss Summary

Operational Highlights and Strategic Outlook

Chandan Healthcare operates through a company-owned model with 360 collection centres and 78+ diagnostic centres and labs. The company conducted 88 lakh+ tests in FY26. Its service portfolio includes NABL/NABH-accredited pathology and radiology solutions. The B2C segment contributed ₹111 Cr (40%) to FY26 revenue, serving 20L+ patients, while B2B and B2G segments each contributed ₹83 Cr (30%).

The company is expanding its footprint into neighboring states including Delhi, Rajasthan, Bihar, Chhattisgarh, Madhya Pradesh, Punjab, Maharashtra, West Bengal, Gujarat, Assam, and Haryana. Future initiatives include launching PET-CT centres at Gorakhpur and Kanpur and a Genome Lab in Lucknow. The company listed on NSE Emerge on February 17, 2025, and its stock price stood at ₹212.75 as on June 22, 2026, with a market capitalization of ₹520.22 Cr.